{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:27:51Z","timestamp":1783535271861,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"institutional grants of the department of pharmacokinetics and therapeutic drug monitoring, pomeranian medical university, szczecin, poland","award":["WLA-129-01\/S\/16\/2016-2020"],"award-info":[{"award-number":["WLA-129-01\/S\/16\/2016-2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Renin-angiotensin system (RAS) influences the central nervous system not only through its peripheral impact\u2014the brain possesses its own local RAS. Studies showed altered RAS components in Parkinson\u2019s disease (PD) and their association with oxidative stress which may be linked to neurodegeneration and dementia. Moreover, the protective functions of RAS blockade antagonists against cognitive decline and dementia have been suggested. This study aimed to examine whether genetic variability in RAS genes correlates with cognitive decline in PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>We genotyped single nucleotide polymorphisms (SNPs) in angiotensinogen (<jats:italic>AGT<\/jats:italic>: rs699, rs4762), angiotensin II receptors (<jats:italic>AGTR1<\/jats:italic>: rs5186 and <jats:italic>AGTR2<\/jats:italic>: rs5194, rs1403543) genes, as well as insertion\/deletion polymorphism in the angiotensin-converting enzyme (<jats:italic>ACE<\/jats:italic> I\/D) gene in 256 PD patients, divided into three groups: without cognitive decline, with mild cognitive impairment and with PD dementia. We did not find any significant differences in the frequencies of the analysed polymorphisms in any of the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite no direct correlation between the investigated polymorphisms in RAS genes and cognitive decline in PD, we believe the impact of those genotypes may be indirect, affecting RAS blockade treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11033-021-06569-6","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T19:03:10Z","timestamp":1627066990000},"page":"5541-5548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-7918","authenticated-orcid":false,"given":"Anna","family":"Pierzchli\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-0877","authenticated-orcid":false,"given":"Jaros\u0142aw","family":"S\u0142awek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-2011","authenticated-orcid":false,"given":"Monika","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8805-7217","authenticated-orcid":false,"given":"Barbara","family":"Gawro\u0144ska-Szklarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-2224","authenticated-orcid":false,"given":"Monika","family":"Bia\u0142ecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"6569_CR1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/ijms19030876","volume":"19","author":"L Jackson","year":"2018","unstructured":"Jackson L, Eldahshan W, Fagan SC, Ergul A (2018) Within the brain: the renin angiotensin system. Int J Mol Sci 19:876. https:\/\/doi.org\/10.3390\/ijms19030876","journal-title":"Int J Mol Sci"},{"key":"6569_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.neurobiolaging.2014.01.017","volume":"35","author":"B Villar-Cheda","year":"2014","unstructured":"Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, Granado N, Moratalla R, Labandeira-Garcia JL (2014) Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol Aging 35:1726\u20131738. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.01.017","journal-title":"Neurobiol Aging"},{"key":"6569_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0006-8993(86)90411-7","volume":"374","author":"CF Deschepper","year":"1986","unstructured":"Deschepper CF, Bouhnik J, Ganong WF (1986) Colocalization of angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain. Brain Res 374:195\u2013198. https:\/\/doi.org\/10.1016\/0006-8993(86)90411-7","journal-title":"Brain Res"},{"key":"6569_CR4","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.3201232","volume":"242","author":"RL Stornetta","year":"1988","unstructured":"Stornetta RL, Hawelu-Johnson CL, Guyenet PG, Lynch KR (1988) Astrocytes synthesize angiotensinogen in brain. Science 242:1444\u20131446. https:\/\/doi.org\/10.1126\/science.3201232","journal-title":"Science"},{"key":"6569_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0009-8981(94)90259-3","volume":"231","author":"CH Konings","year":"1994","unstructured":"Konings CH, Kuiper MA, Bergmans PL, Grijpma AM, van Kamp GJ, Wolters EC (1994) Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson\u2019s disease. Clin Chim Acta 231:101\u2013106. https:\/\/doi.org\/10.1016\/0009-8981(94)90259-3","journal-title":"Clin Chim Acta"},{"key":"6569_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40478-015-0189-z","volume":"3","author":"WM Zawada","year":"2015","unstructured":"Zawada WM, Mrak RE, Biedermann J, Palmer QD, Gentleman SM, Aboud O, Griffin WS (2015) Loss of angiotensin II receptor expression in dopamine neurons in Parkinson\u2019s disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun 3:9. https:\/\/doi.org\/10.1186\/s40478-015-0189-z","journal-title":"Acta Neuropathol Commun"},{"key":"6569_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.nbd.2008.03.003","volume":"31","author":"J Rodriguez-Pallares","year":"2008","unstructured":"Rodriguez-Pallares J, Rey P, Parga JA, Mu\u00f1oz A, Guerra MJ, Labandeira-Garcia JL (2008) Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 31:58\u201373. https:\/\/doi.org\/10.1016\/j.nbd.2008.03.003","journal-title":"Neurobiol Dis"},{"key":"6569_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1470320309347789","volume":"11","author":"B Mertens","year":"2010","unstructured":"Mertens B, Vanderheyden P, Michotte Y, Sarre S (2010) The role of the central renin-angiotensin system in Parkinson\u2019s disease. J Renin Angiotensin Aldosterone Syst 11:49\u201356. https:\/\/doi.org\/10.1177\/1470320309347789","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"6569_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.neurobiolaging.2003.12.010","volume":"25","author":"FL van Muiswinkel","year":"2004","unstructured":"van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, Siegel D, Drukarch B (2004) Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25:1253\u20131262. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2003.12.010","journal-title":"Neurobiol Aging"},{"key":"6569_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ntt.2014.11.004","volume":"47","author":"J Lu","year":"2015","unstructured":"Lu J, Wu L, Jiang T, Wang Y, Zhao H, Gao Q, Pan Y, Tian Y et al (2015) Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson\u2019s disease in CATH.a cells. Neurotoxicol Teratol 47:16\u201324. https:\/\/doi.org\/10.1016\/j.ntt.2014.11.004","journal-title":"Neurotoxicol Teratol"},{"key":"6569_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","volume":"30","author":"KA Reardon","year":"2000","unstructured":"Reardon KA, Mendelsohn FA, Chai SY, Horne MK (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease. Aust N Z J Med 30:48\u201353. https:\/\/doi.org\/10.1111\/j.1445-5994.2000.tb01054.x","journal-title":"Aust N Z J Med"},{"key":"6569_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/jnr.20598","volume":"81","author":"A Lopez-Real","year":"2005","unstructured":"Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL (2005) Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J Neurosci Res 81:865\u2013873. https:\/\/doi.org\/10.1002\/jnr.20598","journal-title":"J Neurosci Res"},{"key":"6569_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neulet.2016.05.003","volume":"624","author":"S Zhuang","year":"2016","unstructured":"Zhuang S, Wang HF, Li J, Wang HY, Wang X, Xing CM (2016) Renin-angiotensin system blockade use and risks of cognitive decline and dementia: a meta-analysis. Neurosci Lett 624:53\u201361. https:\/\/doi.org\/10.1016\/j.neulet.2016.05.003","journal-title":"Neurosci Lett"},{"key":"6569_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jocn.2016.02.036","volume":"33","author":"S Zhuang","year":"2016","unstructured":"Zhuang S, Wang HF, Wang X, Li J, Xing CM (2016) The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer\u2019s disease: a meta-analysis. J Clin Neurosci 33:32\u201338. https:\/\/doi.org\/10.1016\/j.jocn.2016.02.036","journal-title":"J Clin Neurosci"},{"key":"6569_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.parkreldis.2021.03.007","volume":"86","author":"L Udovin","year":"2021","unstructured":"Udovin L, Otero-Losada M, Bordet S, Chevalier G, Quarracino C, Capani F, P\u00e9rez-Lloret S (2021) Effects of angiotensin type 1 receptor antagonists on Parkinson\u2019s disease progression: an exploratory study in the PPMI database. Parkinsonism Relat Disord 86:34\u201337. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.03.007","journal-title":"Parkinsonism Relat Disord"},{"key":"6569_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.parkreldis.2014.06.006","volume":"20","author":"K Zhu","year":"2014","unstructured":"Zhu K, van Hilten JJ, Marinus J (2014) Predictors of dementia in Parkinson\u2019s disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat Disord 20:980\u2013985. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.06.006","journal-title":"Parkinsonism Relat Disord"},{"key":"6569_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","volume":"83","author":"JB Anang","year":"2014","unstructured":"Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83:1253\u20131260. https:\/\/doi.org\/10.1212\/WNL.0000000000000842","journal-title":"Neurology"},{"key":"6569_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S\u00f8rensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387\u2013392. https:\/\/doi.org\/10.1001\/archneur.60.3.387","journal-title":"Arch Neurol"},{"key":"6569_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175560","volume":"12","author":"I Huertas","year":"2017","unstructured":"Huertas I, Jes\u00fas S, Garc\u00eda-G\u00f3mez FJ, Lojo JA, Bernal-Bernal I, Bonilla-Toribio M, Mart\u00edn-Rodriguez JF, Garc\u00eda-Sol\u00eds D et al (2017) Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson\u2019s disease. PLoS ONE 12:e0175560. https:\/\/doi.org\/10.1371\/journal.pone.0175560","journal-title":"PLoS ONE"},{"key":"6569_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1470320313495909","volume":"16","author":"GG Song","year":"2015","unstructured":"Song GG, Lee YH (2015) The insertion\/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson\u2019s disease: a meta-analysis. J Renin Angiotensin Aldosterone Syst 16:434\u2013442. https:\/\/doi.org\/10.1177\/1470320313495909","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"6569_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6569_CR22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22:1689\u20131707. https:\/\/doi.org\/10.1002\/mds.21507","journal-title":"Mov Disord"},{"key":"6569_CR23","doi-asserted-by":"publisher","DOI":"10.4238\/gmr16039779","author":"A Valdez-Haro","year":"2017","unstructured":"Valdez-Haro A, Valle Y, Valdes-Alvarado E, Casillas-Mu\u00f1oz F, Mu\u00f1oz-Valle JF, Reynoso-Villalpando GL, Flores-Salinas HE, Padilla-Guti\u00e9rrez JR (2017) Assessment of the rs4340 ACE gene polymorphism in acute coronary syndrome in a Western Mexican population. Genet Mol Res. https:\/\/doi.org\/10.4238\/gmr16039779","journal-title":"Genet Mol Res"},{"key":"6569_CR24","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI114844","volume":"86","author":"B Rigat","year":"1990","unstructured":"Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343\u20131346. https:\/\/doi.org\/10.1172\/JCI114844","journal-title":"J Clin Invest"},{"key":"6569_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184269","volume":"12","author":"Z Huo","year":"2017","unstructured":"Huo Z, Luo X, Zhan X, Chu Q, Xu Q, Yao J, Pang H (2017) Genetic analysis of indel markers in three loci associated with Parkinson\u2019s disease. PLoS ONE 12:e0184269. https:\/\/doi.org\/10.1371\/journal.pone.0184269","journal-title":"PLoS ONE"},{"key":"6569_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jns.2006.10.018","volume":"252","author":"JJ Lin","year":"2007","unstructured":"Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT (2007) Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson\u2019s disease. J Neurol Sci 252:130\u2013134. https:\/\/doi.org\/10.1016\/j.jns.2006.10.018","journal-title":"J Neurol Sci"},{"key":"6569_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2008.08.017","volume":"276","author":"E Pascale","year":"2009","unstructured":"Pascale E, Purcaro C, Passarelli E, Guglielmi R, Vestri AR, Passarelli F, Meco G (2009) Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson\u2019s disease and of l-dopa-induced adverse effects. J Neurol Sci 276:18\u201321. https:\/\/doi.org\/10.1016\/j.jns.2008.08.017","journal-title":"J Neurol Sci"},{"key":"6569_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neurobiolaging.2008.07.015","volume":"31","author":"DR Gustafson","year":"2010","unstructured":"Gustafson DR, Melchior L, Eriksson E, Sundh V, Blennow K, Skoog I (2010) The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging 31:910\u2013916. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.07.015","journal-title":"Neurobiol Aging"},{"key":"6569_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jagp.2016.06.009","volume":"25","author":"A Zettergren","year":"2017","unstructured":"Zettergren A, Kern S, Gustafson D, Gudmundsson P, Sigstr\u00f6m R, \u00d6stling S, Eriksson E, Zetterberg H et al (2017) The ACE gene is associated with late-life major depression and age at dementia onset in a population-based cohort. Am J Geriatr Psychiatry 25:170\u2013177. https:\/\/doi.org\/10.1016\/j.jagp.2016.06.009","journal-title":"Am J Geriatr Psychiatry"},{"key":"6569_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.pjnns.2018.04.003","volume":"52","author":"A Pierzchli\u0144ska","year":"2018","unstructured":"Pierzchli\u0144ska A, Bia\u0142ecka M, Kurzawski M, S\u0142awek J (2018) The impact of apolipoprotein E alleles on cognitive performance in patients with Parkinson\u2019s disease. Neurol Neurochir Pol 52:477\u2013482. https:\/\/doi.org\/10.1016\/j.pjnns.2018.04.003","journal-title":"Neurol Neurochir Pol"},{"key":"6569_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/WAD.0b013e3181d71a13","volume":"24","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Kim JS, Yoo JY, Song IU, Kim BS, Jung SL, Yang DW, Kim YI et al (2010) Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 24:227\u2013233. https:\/\/doi.org\/10.1097\/WAD.0b013e3181d71a13","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"6569_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000338610","volume":"12","author":"J S\u0142awek","year":"2013","unstructured":"S\u0142awek J, Roszmann A, Robowski P, Dubaniewicz M, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S et al (2013) The impact of MRI white matter hyperintensities on dementia in Parkinson\u2019s disease in relation to the homocysteine level and other vascular risk factors. Neurodegener Dis 12:1\u201312. https:\/\/doi.org\/10.1159\/000338610","journal-title":"Neurodegener Dis"},{"key":"6569_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00415-020-10189-8","volume":"268","author":"A Nicoletti","year":"2021","unstructured":"Nicoletti A, Luca A, Baschi R, Cicero CE, Mostile G, Dav\u00ec M, La Bianca G, Restivo V, Zappia M, Monastero R (2021) Vascular risk factors, white matter lesions and cognitive impairment in Parkinson\u2019s disease: the PACOS longitudinal study. J Neurol 268:549\u2013558. https:\/\/doi.org\/10.1007\/s00415-020-10189-8","journal-title":"J Neurol"},{"key":"6569_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/hbm.21445","volume":"34","author":"WD Taylor","year":"2013","unstructured":"Taylor WD, Zhao Z, Ashley-Koch A, Payne ME, Steffens DC, Krishnan RR, Hauser E, MacFall JR (2013) Fiber tract-specific white matter lesion severity findings in late-life depression and by AGTR1 A1166C genotype. Hum Brain Mapp 34:295\u2013303. https:\/\/doi.org\/10.1002\/hbm.21445","journal-title":"Hum Brain Mapp"},{"key":"6569_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/01677063.2011.556206","volume":"25","author":"OH Gebril","year":"2011","unstructured":"Gebril OH, Kirby J, Savva G, Brayne C, Ince PG (2011) HFE H63D, C282Y and AGTR1 A1166C polymorphisms and brain white matter lesions in the aging brain. J Neurogenet 25:7\u201314. https:\/\/doi.org\/10.3109\/01677063.2011.556206","journal-title":"J Neurogenet"},{"key":"6569_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbr.2015.08.028","volume":"296","author":"LE Salminen","year":"2016","unstructured":"Salminen LE, Schofield PR, Pierce KD, Zhao Y, Luo X, Wang Y, Laidlaw DH, Cabeen RP, Conturo TE, Tate DF, Akbudak E, Lane EM, Heaps JM, Bolzenius JD, Baker LM, Cagle LM, Paul RH (2016) Neuromarkers of the common angiotensinogen polymorphism in healthy older adults: a comprehensive assessment of white matter integrity and cognition. Behav Brain Res 296:85\u201393. https:\/\/doi.org\/10.1016\/j.bbr.2015.08.028","journal-title":"Behav Brain Res"},{"key":"6569_CR37","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1532-5415.2010.02860.xs","volume":"58","author":"I Hajjar","year":"2010","unstructured":"Hajjar I, Kritchevsky S, Newman AB, Li R, Yaffe K, Simonsick EM, Lipsitz LA (2010) Renin angiotensin system gene polymorphisms modify angiotensin-converting enzyme inhibitors\u2019 effect on cognitive function: the health, aging and body composition study. J Am Geriatr Soc 58:1035\u20131042. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02860.xs","journal-title":"J Am Geriatr Soc"},{"key":"6569_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.18632\/aging.101419","volume":"10","author":"T Jiang","year":"2018","unstructured":"Jiang T, Xue LJ, Yang Y, Wang QG, Xue X, Ou Z, Gao Q, Shi JQ, Wu L, Zhang YD (2018) AVE0991, a nonpeptide analogue of Ang-(1\u20137), attenuates aging-related neuroinflammation. Aging 10:645\u2013657. https:\/\/doi.org\/10.18632\/aging.101419","journal-title":"Aging"},{"key":"6569_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00401-019-02098-6","volume":"139","author":"CE Evans","year":"2020","unstructured":"Evans CE, Miners JS, Piva G, Willis CL, Heard DM, Kidd EJ, Good MA, Kehoe PG (2020) ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer\u2019s disease. Acta Neuropathol 139:485\u2013502. https:\/\/doi.org\/10.1007\/s00401-019-02098-6","journal-title":"Acta Neuropathol"},{"key":"6569_CR40","doi-asserted-by":"publisher","first-page":"147032031666675","DOI":"10.1177\/1470320316666750","volume":"17","author":"B Goldstein","year":"2016","unstructured":"Goldstein B, Speth RC, Trivedi M (2016) Renin-angiotensin system gene expression and neurodegenerative diseases. J Renin Angiotensin Aldosterone Syst 17:1470320316666750. https:\/\/doi.org\/10.1177\/1470320316666750","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"6569_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jns.2016.07.031","volume":"368","author":"NP Rocha","year":"2016","unstructured":"Rocha NP, Scalzo PL, Barbosa IG, de Campos-Carli SM, Tavares LD, de Souza MS, Christo PP, Reis HJ, Sim\u00f5es E, Silva AC, Teixeira AL (2016) Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson\u2019s disease. J Neurol Sci 368:235\u2013239. https:\/\/doi.org\/10.1016\/j.jns.2016.07.031","journal-title":"J Neurol Sci"},{"key":"6569_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1567202613666160224124739","volume":"13","author":"T Jiang","year":"2016","unstructured":"Jiang T, Tan L, Gao Q, Lu H, Zhu XC, Zhou JS, Zhang YD (2016) Plasma angiotensin-(1\u20137) is a potential biomarker for Alzheimer\u2019s disease. Curr Neurovasc Res 13:96\u201399. https:\/\/doi.org\/10.2174\/1567202613666160224124739","journal-title":"Curr Neurovasc Res"},{"key":"6569_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.636754","volume":"15","author":"VT Ribeiro","year":"2021","unstructured":"Ribeiro VT, Cordeiro TME, Filha RDS, Perez LG, Caramelli P, Teixeira AL, de Souza LC, Sim\u00f5es E, Silva AC (2021) Circulating angiotensin-(1\u20137) Is reduced in Alzheimer\u2019s disease patients and correlates with white matter abnormalities: results from a pilot study. Front Neurosci 15:636754. https:\/\/doi.org\/10.3389\/fnins.2021.636754","journal-title":"Front Neurosci"},{"key":"6569_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","volume":"8","author":"PG Kehoe","year":"2016","unstructured":"Kehoe PG, Wong S, Al Mulhim N, Palmer LE, Miners JS (2016) Angiotensin-converting enzyme 2 is reduced in Alzheimer\u2019s disease in association with increasing amyloid-\u03b2 and tau pathology. Alzheimers Res Ther 8:50. https:\/\/doi.org\/10.1186\/s13195-016-0217-7","journal-title":"Alzheimers Res Ther"},{"key":"6569_CR45","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/ijms22041687","volume":"22","author":"Q Ding","year":"2021","unstructured":"Ding Q, Shults NV, Gychka SG, Harris BT, Suzuki YJ (2021) Protein expression of angiotensin-converting enzyme 2 (ACE2) is upregulated in brains with Alzheimer\u2019s disease. Int J Mol Sci 22:1687. https:\/\/doi.org\/10.3390\/ijms22041687","journal-title":"Int J Mol Sci"},{"key":"6569_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.573095","volume":"11","author":"R Chen","year":"2021","unstructured":"Chen R, Wang K, Yu J, Howard D, French L, Chen Z, Wen C, Xu Z (2021) The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol 11:573095. https:\/\/doi.org\/10.3389\/fneur.2020.573095","journal-title":"Front Neurol"},{"key":"6569_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(20)30442-7","volume":"20","author":"M Merello","year":"2021","unstructured":"Merello M, Bhatia KP, Obeso JA (2021) SARS-CoV-2 and the risk of Parkinson\u2019s disease: facts and fantasy. Lancet Neurol 20:94\u201395. https:\/\/doi.org\/10.1016\/S1474-4422(20)30442-7","journal-title":"Lancet Neurol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06569-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T19:09:06Z","timestamp":1628104146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6569"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06569-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (The Bioethics Committee of the Pomeranian Medical University, KB-0012\/151\/15) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}